Update on gout and hyperuricemia


  • Disclosures Dr Schumacher is a consultant for Takeda, Ipsen, Savient, Regeneron.

Joshua F. Baker, Department of Medicine, Division of Rheumatology, Hospital of the University of Pennsylvania, 5 Maloney Building, Suite 504, 3600 Spruce Street, Philadelphia, PA 19104, USA
Tel.: + 1 215 662 4659
Fax: + 1 215 662 4500
Email: bakerjo@uphs.upenn.edu


There have been recent advances in the understanding of underlying mechanisms and treatment of gout and chronic hyperuricemia, making this an important time to review the current state of the disease. The goal of this article is to provide a practical review of the current standard of care as well as discuss some new developments in the management. There is an increasing prevalence of gout and hyperuricemia worldwide. Gout confers a significant individual and societal burden and is often under-treated. Appropriate diagnosis and treatment of acute gout should be followed by aggressive and goal-oriented treatment of hyperuricemia and other risk factors. Allopurinol remains as a first-line treatment for chronic hyperuricemia, but uricosuric agents may also be considered in some patients. Febuxostat, a non-purine xanthine-oxidase inhibitor, is a new agent approved for the treatment of hyperuricemia in patients with gout, which may be used when allopurinol is contraindicated. Gout and hyperuricemia appear to be independent risk factors for incident hypertension, renal disease and cardiovascular disease. Physicians should consider cardiovascular risk factors in patients with gout and treat them appropriately and aggressively.